AKT1 and neoplasm: Finally, the anti-tumor potency associated with down-regulation of GLUT-1 by FGFR1 and AKT/mTOR co-targeted inhibition was confirmed also in vivo, further strengthening the contention that tackling on cancer glucose metabolism may offer a new therapeutic option for the treatment of SQCLC.